US 12,351,626 B2
Anti-human interleukin-33 monoclonal antibody and use thereof
Jiwan Qiu, Jiangsu (CN); Wei Chen, Jiangsu (CN); Yong Kong, Jiangsu (CN); Huaiyao Qiao, Jiangsu (CN); Yiliang Wu, Jiangsu (CN); Tao Chen, Jiangsu (CN); and Meijuan Wu, Jiangsu (CN)
Assigned to QYUNS THERAPEUTICS CO., LTD., Jiangsu (CN)
Filed by QYUNS THERAPEUTICS CO., LTD., Jiangsu (CN)
Filed on Mar. 1, 2024, as Appl. No. 18/593,108.
Application 18/593,108 is a continuation of application No. PCT/CN2021/136755, filed on Dec. 9, 2021.
Claims priority of application No. 202111031678.2 (CN), filed on Sep. 3, 2021.
Prior Publication US 2024/0309081 A1, Sep. 19, 2024
Int. Cl. C07K 16/24 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 39/3955 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 7 Claims
 
1. An isolated anti-human interleukin-33 monoclonal antibody, comprising three heavy chain complementarity determining regions and three light chain complementarity determining regions, the three heavy chain complementarity determining regions are CDR-H1, CDR-H2 and CDR-H3, and the three light chain complementarity determining regions are CDR-L1, CDR-L2 and CDR-L3, wherein:
the amino acid sequence of CDR-H1 is represented by SEQ ID NO: 1;
the amino acid sequence of CDR-H2 is represented by SEQ ID NO: 2;
the amino acid sequence of CDR-H3 is represented by SEQ ID NO: 3;
the amino acid sequence of CDR-L1 is represented by SEQ ID NO: 4;
the amino acid sequence of CDR-L2 is represented by SEQ ID NO: 5; and
the amino acid sequence of CDR-L3 is represented by SEQ ID NO: 6.